Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial.

Int Immunopharmacol · 2020 · PMC7553010 · PMID 33075713

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

By contrast, in one other meta-analysis [46] , the beneficial impact of tocilizumab on COVID-19 mortality did not reach statistical significance (RR of 0.62, 95% CI of 0.31–1.22), and data from these studies are conflicting.

also in 111,027 other papers

a positive trendno p-value reported

However, in the COVACTA trial, only a positive trend in the time to hospital discharge was observed in the tocilizumab group, and the trial did not meet the main endpoints of significant improvements in clinical status and survival rate.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.